Abstract
Production of retroviral vectors for clinical use requires removal of cells and cellular debris. We combined a series of filters of decreasing pore size using commercially available blood banking filters approved for clinical use. The collection bag and filters can be connected to create a sterile, closed system using clinically approved tubing and sealing systems. Even when challenged with a large number of vector producer cells (2.38 × 109cells), no viable cells are passed through the system. The step filtration system developed minimizes the titer reduction associated with filtration, provides rapid flow rates, and was cost effective when filtering volumes in excess of 2 liters.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Reeves L, Smucker P, Cornetta K . Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience Hum Gene Ther 2000 11: 2093–2103
Le Doux JM, Morgan JR, Snow RG, Yarmush ML . Proteoglycans secreted by packaging cell lines inhibit retrovirus infection J Virol 1996 70: 6468–6473
Braas G, Searle PF, Slater NKH, Lyddiatt A . Strategies for the isolation and purification of retroviral vectors for gene therapy Bioseparation 1996 6: 211–228
Kotani H et al. Improved methods of retroviral vector transduction and production for gene therapy Hum Gene Ther 1994 5: 19–28
Bowles NE et al. A simple and efficient method for concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo Hum Gene Ther 1996 7: 1735–1742
McGrath M, Witte O, Pincus T, Weissman IL . Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity J Virol 1978 25: 923–927
Lyddiatt A, O'Sullivan DA . Biochemical recovery and purification of gene therapy vectors Curr Opin Biotechnol 1998 9: 177–185
Hammar L . Concentration of biomaterials: virus concentration and viral protein isolation Meth Enzymol 1994 228: 640–658
Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease Science 2000 288: 669–672
Abonour R et al. Efficient retroviral-mediated MDR-1 gene transfer into autologous human long-term repopulating hematopoietic stem cells Nature Med 2000 6: 652–658
Miller AD et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus J Virol 1991 65: 2220–2224
Miller AD, Buttimore C . Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production Mol Cell Biol 1986 6: 2895–2902
Markowitz D, Goff S, Bank A . A safe packaging line for gene transfer: separating viral genes on two different plasmids J Virol 1988 62: 1120–1124
Markowitz D, Goff S, Bank A . Construction and use of a safe and efficient amphotropic packaging line Virology 1988 167: 400–406
Bierhuizen MF et al. Enhanced gene fluorescent protein as selectable marker of retroviral-mediated gene transfer in immature hematopoietic bone marrow cells Blood 1997 90: 3304–3315
Acknowledgements
We are indebted to Dr Philip Maples for his technical advice in filter selection. We would like to thank Christine Starkey, Clara Hazelgrove and Lisa Woodsides for their technical contributions to this manuscript. The Indiana University Vector Production Facility is a NIH designated National Gene Vector Laboratory (U42 RR11148) and this work was supported in part by a Centers of Excellence in Molecular Hematology grant (PHS P50 DK49218) and a core laboratory supporting PHS P01 HL53586.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reeves, L., Cornetta, K. Clinical retroviral vector production: step filtration using clinically approved filters improves titers. Gene Ther 7, 1993–1998 (2000). https://doi.org/10.1038/sj.gt.3301328
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301328
Keywords
This article is cited by
-
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies
Cancer Gene Therapy (2015)
-
Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion
Cancer Immunology, Immunotherapy (2010)
-
Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factories
Gene Therapy (2006)
-
Retroviral vector production in the National Gene Vector Laboratory at Indiana University
Gene Therapy (2005)